0000899243-18-019717.txt : 20180710
0000899243-18-019717.hdr.sgml : 20180710
20180710181016
ACCESSION NUMBER: 0000899243-18-019717
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180706
FILED AS OF DATE: 20180710
DATE AS OF CHANGE: 20180710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Calhoun Lesley Ann
CENTRAL INDEX KEY: 0001730866
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 18947738
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BOULEVARD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-07-06
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001730866
Calhoun Lesley Ann
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD., SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Common Stock
2018-07-06
4
M
0
1000
22.00
A
1388
D
Common Stock
2018-07-06
4
S
0
1000
44.005
D
388
D
Common Stock
2018-07-09
4
M
0
2295
22.00
A
2683
D
Common Stock
2018-07-09
4
S
0
2295
44.274
D
388
D
Stock Option (Right to Buy)
22.00
2018-07-06
4
M
0
1000
0.00
D
2026-08-14
Common Stock
1000
29000
D
Stock Option (Right to Buy)
22.00
2018-07-09
4
M
0
2295
0.00
D
2026-08-14
Common Stock
2295
26705
D
The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Vice President, Finance and Principal Accounting Officer
/s/ Lesley Ann Calhoun
2018-07-10